The relationship between venous thromboembolism and cancer has been known for many years, and there is solid scientific evidence addressing the adequate treatment of this condition in oncology patients. However, established prescribing habits, individual patient challenges, and uncertainty concerning treatment justifies poor adherence to published guidelines. This paper reviews venous thromboembolism treatment while focusing on vitamin K antagonists, low-molecular-weight heparins, and novel oral anticoagulants, namely in terms of their efficacy and limitations
Venous thromboembolism (VTE) is a frequent complication in cancer patients, and represents an import...
Venous thromboembolism (VTE) is a frequent complication in patients with cancer and is associated wi...
Abstract Background Cancer and its therapies increase the risk of venous thromboembolism. Compared t...
Cancer represents a well recognized risk factor for venous thromboembolism. Patients with cancer hav...
The association between venous thromboembolism and cancer has been recognized for over 140 years. Th...
The association between cancer and venous thromboembolism (VTE) has been established for more than 1...
Cancer disease is one of the most significant risk factors for venous thromboembolic complications. ...
Patients with cancer are at a high risk of symptomatic venous thromboembolism (VTE), which is a comm...
Cancer-associated venous thromboembolism is a devastating complication of cancer and is associated w...
Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at i...
Introduction: Cancer and venous thromboembolism (VTE) are closely related, with a high risk of VTE a...
Therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer remai...
Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Emerging d...
This is a narrative review of the relevant literature on the epidemiology, pathogenesis, and treatme...
Cancer patients are at major risk of developing venous thromboembolism (VTE), resulting in increased...
Venous thromboembolism (VTE) is a frequent complication in cancer patients, and represents an import...
Venous thromboembolism (VTE) is a frequent complication in patients with cancer and is associated wi...
Abstract Background Cancer and its therapies increase the risk of venous thromboembolism. Compared t...
Cancer represents a well recognized risk factor for venous thromboembolism. Patients with cancer hav...
The association between venous thromboembolism and cancer has been recognized for over 140 years. Th...
The association between cancer and venous thromboembolism (VTE) has been established for more than 1...
Cancer disease is one of the most significant risk factors for venous thromboembolic complications. ...
Patients with cancer are at a high risk of symptomatic venous thromboembolism (VTE), which is a comm...
Cancer-associated venous thromboembolism is a devastating complication of cancer and is associated w...
Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at i...
Introduction: Cancer and venous thromboembolism (VTE) are closely related, with a high risk of VTE a...
Therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer remai...
Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Emerging d...
This is a narrative review of the relevant literature on the epidemiology, pathogenesis, and treatme...
Cancer patients are at major risk of developing venous thromboembolism (VTE), resulting in increased...
Venous thromboembolism (VTE) is a frequent complication in cancer patients, and represents an import...
Venous thromboembolism (VTE) is a frequent complication in patients with cancer and is associated wi...
Abstract Background Cancer and its therapies increase the risk of venous thromboembolism. Compared t...